Benitec Biopharma (NASDAQ:BNTC) Stock Price Expected to Rise, Wedbush Analyst Says

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) had its target price raised by research analysts at Wedbush from $17.00 to $20.00 in a report released on Monday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Wedbush‘s target price would indicate a potential upside of 121.24% from the stock’s current price.

BNTC has been the subject of several other reports. HC Wainwright restated a “buy” rating on shares of Benitec Biopharma in a research report on Monday, November 2nd. Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a report on Tuesday, October 6th. Wall Street Zen cut Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. Royal Bank Of Canada raised Benitec Biopharma to an “outperform” rating in a research report on Tuesday, September 15th. Finally, Raymond James Financial initiated coverage on Benitec Biopharma in a report on Friday, October 23rd. They issued an “outperform” rating and a $14.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.75.

Check Out Our Latest Analysis on Benitec Biopharma

Benitec Biopharma Stock Performance

Shares of BNTC opened at $9.04 on Monday. The stock has a market cap of $315.41 million, a P/E ratio of -8.86 and a beta of 0.26. The company has a 50-day moving average of $9.67 and a two-hundred day moving average of $11.39. Benitec Biopharma has a 12-month low of $7.89 and a 12-month high of $14.39.

Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. As a group, analysts forecast that Benitec Biopharma will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. purchased a new stake in shares of Benitec Biopharma during the 2nd quarter valued at $2,515,000. Bank of New York Mellon Corp purchased a new position in shares of Benitec Biopharma in the 2nd quarter worth $804,000. Nantahala Capital Management LLC boosted its holdings in Benitec Biopharma by 12.7% in the third quarter. Nantahala Capital Management LLC now owns 1,677,567 shares of the biotechnology company’s stock valued at $16,776,000 after acquiring an additional 189,196 shares during the last quarter. Bank of America Corp DE boosted its holdings in Benitec Biopharma by 43.3% in the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock valued at $185,000 after acquiring an additional 5,251 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Benitec Biopharma by 18.7% in the second quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock valued at $107,000 after acquiring an additional 1,256 shares during the last quarter. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

(Get Free Report)

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.

Further Reading

Analyst Recommendations for Benitec Biopharma (NASDAQ:BNTC)

Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.